David R. Gandara, MD, discusses why PD-L1 scoring in NSCLC undercounts immunotherapy benefit and where TMB and plasma proteomics fit alongside it.
|Videos|May 18, 2011
Dr. Markman Discusses the Swedish PSA Screening
Author(s)Maurie Markman, MD
Dr. Markman Discusses the Swedish PSA Screening
Advertisement
Maurie Markman, MD the National Director for Medical Oncology for the Cancer Treatment Centers of America Discusses the Swedish PSA Screening Study
Advertisement
Related to this article
Edgardo S. Santos Castillero, MD, discusses MAVERICK, B7-H3 ADC data, and tarlatamab sequencing in SCLC, plus molecular testing in a value-based practice.
Advertisement
Advertisement
Trending on OncLive
1
NAPISTAR-1-01 Data Support Rapid TUB-040 Development in Biomarker-Unrestricted Ovarian Cancer
2
FDA Grants Fast Track Designation to LYT-200 in R/R High-Risk MDS
3
Japan Approves Subcutaneous Pembrolizumab for All Approved Pembrolizumab Indications
4
Making Invisible Cancers Visible: Study Suggests a New Route to Turn ‘Cold’ Tumors ‘Hot’
5